Manchester, CT – According to filings with the U.S. Securities and Exchange Commission, Diant Pharma is raising $4,752,220.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Antonio Costa played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Diant Pharma
DIANT Pharma has developed a continuous processing technology applicable for nanoparticle drug products and vaccines. We strive to offer a technology that is robust and reliable from R&D to manufacturing; over a products lifespan. Our proprietary continuous manufacturing system for nanoparticles has a wide array of applications within the pharmaceutical space. An R&D nanoparticle synthesis system scalable to the DIANT LiFT. Suitable for R&D and academic work. Offers a small size to fit on a lab bench and can continuously produce lipid and polymer-based nanoparticles. The system can operate in batch or continuous operation, with short duration runs of 30 seconds to long duration runs. Maximum output flow rate is 400 mL/min.

To learn more about Diant Pharma, visit http://diantpharma.com/

Contact:
Antonio Costa, Chief Executive Officer
774-462-2227
https://www.linkedin.com/in/antonio-costa-30475280/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved